References:
[1] Wu F, Zhao S, Yu B, Chen YM, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579:265–269.
[2] Gupta, A., Madhavan, M.V., Sehgal, K. et al.  Extrapulmonary manifestations of COVID-19. Nat Med  26,  1017–1032 (2020). https://doi.org/10.1038/s41591-020-0968-3
[3] Li YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. J Med Virol. 2020;92:552–555.
[4] Zhang Y, Xiao M, Zhang S, et al. Coagulopathy and antiphospholipid antibodies in patients with covid-19. N Engl J Med. 2020.
[5] Toscano G, Palmerini F, Ravaglia S, Ruiz L, Invernizzi P, Cuzzoni MG, Franciotta D, Baldanti F, Daturi R, Postorino P, Cavallini A, Micieli G. Guillain–Barré syndrome associated with SARS-CoV-2. New Engl J Med. 2020;382:2574–2576.
[6] Gutiérrez-Ortiz C, Méndez A, Rodrigo-Rey S, San Pedro-Murillo E, Bermejo-Guerrero L, Gordo-Mañas R, de Aragón-Gómez F, Benito-León J. Miller Fisher Syndrome and polyneuritis cranialis in COVID-19. Neurology 2020. doi: 10.1212/WNL.0000000000009619.
[7] Jones VG, Mills M, Suarez D, Hogan CA, Yeh D, Bradley Segal J, Nguyen EL, Barsh GR, Maskatia S, Mathew R. COVID-19 and Kawasaki disease: novel virus and novel case. Hosp Pediatr. 2020;10:537–540.
[8] Montalvan V, Lee J, Bueso T, De Toledo J, Rivas K. Neurological manifestations of COVID-19 and other coronavirus infections: A systematic review. Clin Neurol Neurosurg . 2020;194:105921. doi:10.1016/j.clineuro.2020.105921
[9] Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China [published online ahead of print, 2020 Feb 7]. JAMA . 2020;323(11):1061-1069. doi:10.1001/jama.2020.1585
[10] Croft PB. Para-infectious and post-vaccinal encephalomyelitis. Postgrad Med J . 1969;45(524):392-400. doi:10.1136/pgmj.45.524.392
[11] Lana-Peixoto MA, Talim N. Neuromyelitis Optica Spectrum Disorder and Anti-MOG Syndromes. Biomedicines . 2019;7(2):42. Published 2019 Jun 12. doi:10.3390/biomedicines7020042
[12] Mealy MA, Wingerchuk DM, Greenberg BM, Levy M. Epidemiology of neuromyelitis optica in the United States: a multicenter analysis. Arch Neurol . 2012;69(9):1176-1180. doi:10.1001/archneurol.2012.314
[13] Mori M, Kuwabara S, Paul F. Worldwide prevalence of neuromyelitis optica spectrum disorders. J Neurol Neurosurg Psychiatry . 2018;89(6):555-556. doi:10.1136/jnnp-2017-317566
[14]  Jurynczyk M., Tackley G., Kong Y., Geraldes R., Matthews L., Woodhall M., Waters P., Kuker W., Craner M., Weir A., et al. Brain lesion distribution criteria distinguish ms from aqp4-antibody nmosd and mog-antibody disease. J. Neurol. Neurosurg. Psychiatry. 2017;88:132–136. doi: 10.1136/jnnp-2016-314005.
[15] Merabtene L, Vignal Clermont C, Deschamps R. Neuropathie optique dans le syndrome des anticorps anti MOG positif [Optic neuropathy in positive anti-MOG antibody syndrome]. J Fr Ophtalmol . 2019;42(10):1100-1110. doi:10.1016/j.jfo.2019.06.006
[16] Hamid SHM, Whittam D, Mutch K, et al. What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients. J Neurol . 2017;264(10):2088-2094. doi:10.1007/s00415-017-8596-7
[17] Kim SH, Mealy MA, Levy M, et al. Racial differences in neuromyelitis optica spectrum disorder. Neurology . 2018;91(22):e2089-e2099. doi:10.1212/WNL.0000000000006574
[18] Jarius S, Ruprecht K, Kleiter I, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation . 2016;13(1):280. Published 2016 Sep 27. doi:10.1186/s12974-016-0718-0
[19] Berger T, Rubner P, Schautzer F, et al. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med . 2003;349(2):139-145. doi:10.1056/NEJMoa022328
[20] Ramanathan S, Mohammad S, Tantsis E, et al. Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. J Neurol Neurosurg Psychiatry . 2018;89(2):127-137. doi:10.1136/jnnp-2017-316880
[21] Reindl M, Di Pauli F, Rostásy K, Berger T. The spectrum of MOG autoantibody-associated demyelinating diseases. Nat Rev Neurol . 2013;9(8):455-461. doi:10.1038/nrneurol.2013.118
[22] Croft PB. Para-infectious and post-vaccinal encephalomyelitis. Postgrad Med J . 1969;45(524):392-400. doi:10.1136/pgmj.45.524.392
[23] Zhou S, Jones-Lopez EC, Soneji DJ, Azevedo CJ, Patel VR. Myelin Oligodendrocyte Glycoprotein Antibody-Associated Optic Neuritis and Myelitis in COVID-19. J Neuroophthalmol . 2020;40(3):398-402. doi:10.1097/WNO.0000000000001049
[24] Mondragon J, Klovenski V. Pseudotumor Cerebri. [Updated 2020 Jul 10]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK536924/
[25] Fujihara K, Bennett JL, de Seze J, Haramura M, Kleiter I, Weinshenker BG, Kang D, Mughal T, Yamamura T. Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology. Neurology-Neuroimmunology Neuroinflammation. 2020 Sep 3;7(5).